Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | TSPO | P30536 | 1/20 | 0.52 |
| ▸ | GABRA1 | P14867 | 10/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 10/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 10/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 9/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 9/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 9/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.50 |
| ▸ | GABRP | O00591 | 2/20 | 0.50 |
| ▸ | GABRD | O14764 | 2/20 | 0.50 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.50 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.50 |
| ▸ | GABRE | P78334 | 2/20 | 0.50 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.50 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.50 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.50 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5044354 | 0.89 | PDE2A (0.52) | PDE2ALMNAGAATSPOGABRA1 | |
| SCHEMBL5044322 | 0.89 | LMNA (0.55) | PDE2ALMNAGAATSPOGABRA1 | |
| SCHEMBL5042534 | 0.89 | PDE2A (0.66) | PDE2ALMNAGAATSPOGABRA1 | |
| SCHEMBL5037313 | 0.89 | LMNA (0.55) | PDE2ALMNAGAATSPOGABRA1 | |
| SCHEMBL5034683 | 0.88 | GABRA1 (0.60) | PDE2ALMNAGAATSPOGABRA1 | |
| SCHEMBL5037509 | 0.87 | PDE2A (0.72) | PDE2ALMNAGAATSPOGABRA1 | |
| SCHEMBL5034691 | 0.86 | GABRA1 (0.63) | PDE2ALMNAGAATSPOGABRA1 | |
| SCHEMBL5488783 | 0.85 | PDE2A (0.68) | PDE2ALMNAGAATSPOGABRA1 | |
| SCHEMBL6030620 | 0.84 | LMNA (0.53) | PDE2ALMNAGAATSPOGABRA1 | |
| SCHEMBL5034629 | 0.84 | GABRA1 (0.63) | PDE2ALMNAGAATSPOGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7410963-B2 | To treat diseases associated with abnormal regulation of intracellular cAMP and/or cGMP rate and abnormal regulation of neurotransmitter effect, with no perturbating effect on memory; autoinflammatory disorders; 3-(8-Methoxy-1-methyl-2-oxo-7-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)-benzonitrile | VIA PHARMACEUTICALS, INC. (US) | 2008-08-12 | — | — | US | claimed |
| US-20070123519-A1 | Benzo-1,4-diazepin-2-one derivatives as phosphodiesterase pde2 inhibitors, preparation and therapeutic use thereof | BAY CITY CAPITAL LLC | 2007-05-31 | — | — | US | claimed |
| US-7410963-B2 | To treat diseases associated with abnormal regulation of intracellular cAMP and/or cGMP rate and abnormal regulation of neurotransmitter effect, with no perturbating effect on memory; autoinflammatory disorders; 3-(8-Methoxy-1-methyl-2-oxo-7-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)-benzonitrile | VIA PHARMACEUTICALS, INC. (US) | 2008-08-12 | — | — | US | disclosed |
| US-20070123519-A1 | Benzo-1,4-diazepin-2-one derivatives as phosphodiesterase pde2 inhibitors, preparation and therapeutic use thereof | BAY CITY CAPITAL LLC | 2007-05-31 | — | — | US | disclosed |
| EP-1697332-A1 | BENZO'1,4 ! DIAZEPIN-2-ONE DERIVATIVES AS PHOSPHODIESTERASE PDE2 INHIBITORS, PREPARATION AND THERAPEUTIC USE THEREOF | NEURO3D (FR) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005063723-A1 | BENZO`1,4 ! DIAZEPIN-2-ONE DERIVATIVES AS PHOSPHODIESTERASE PDE2 INHIBITORS, PREPARATION AND THERAPEUTIC USE THEREOF | NEURO3D (FR) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123519-A1 | Benzo-1,4-diazepin-2-one derivatives as phosphodiesterase pde2 inhibitors, preparation and therapeutic use thereof | PDE12, PDE2A, PDE3A | PDE2A 2/4885LMNA 1921/4885GAA 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.